Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer

International Journal of Urology

Volumn 15, Issue 6, 2008, Pages 520-523

  Nishimoto, Koshiro ^a   Nakashima, Jun ^a   Hashiguchi, Akinori ^a   Kikuchi, Eiji ^a   Miyajima, Akira ^a   Nakagawa, Ken ^a   Ohigashi, Takashi ^a   Oya, Mototsugu ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Extraprostatic extension; Gleason score; Prediction; PSA velocity; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; BIOPSY; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM;

EID: 44049085753     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02042.x     Document Type: Article

References (25)

1. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 2002 167 : 528 34.
2. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 : 1445 51.
3. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001 58 : 843 8.
4. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993 150 : 110 14.
5. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J. Urol. 2001 165 : 1562 8.
6. Perrotti M, Pantuck A, Rabbani F, Israeli RS, Weiss RE. Review of staging modalities in clinically localized prostate cancer. Urology 1999 54 : 208 14.
7. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J. Urol. 1999 162 : 293 306.
8. Furuya Y, Ohta S, Sato N et al. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. Anticancer Res. 2001 21 : 1317 20.
9. Graefen M, Karakiewicz PI, Cagiannos I et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 2002 167 : 1306 9.
10. Hara I, Miyake H, Hara S et al. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int. 2001 88 : 53 7.
11. Kurita Y, Suzuki A, Masuda H, Ushiyama T, Suzuki K, Fujita K. Transition zone volume -adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels. Eur. Urol. 1998 33 : 32 8.
12. Melchior SW, Noteboom J, Gillitzer R, Lange PH, Blumenstein BA, Vessella RL. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU Int. 2001 88 : 221 5.
13. Morote J, Encabo G, de Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur. Urol. 2000 38 : 225 9.
14. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol. 1998 159 : 1238 42.
15. Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology 1997 49 : 716 20.
16. Tombal B, Querton M, de Nayer P et al. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology 2002 59 : 256 60.
17. Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/mL. J. Urol. 1998 160 : 2089 95.
18. Horiguchi A, Nakashima J, Horiguchi Y et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 2003 56 : 23 9.
19. Egawa S, Arai Y, Tobisu K et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 2000 3 : 269 74.
20. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 2004 351 : 125 35.
21. Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004 64 : 101 5.
22. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. North Am. 1993 20 : 665 70.
23. Cornud F, Flam T, Chauveinc L et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002 224 : 203 10.
24. Ikonen S, Karkkainen P, Kivisaari L et al. Magnetic resonance imaging of prostatic cancer: does detection vary between high and low Gleason score tumors? Prostate 2000 43 : 43 8.
25. Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J. Urol. 1997 158 : 1876 8 discussion 8 9.